Frank Dennis Saylor IV

U.S. District Court for the District of Massachusetts Appointed by George W. Bush (Republican) 19 signed orders read

How Judge IV decides

Patterns drawn from this judge's own signed orders. Every observation links to the order it came from.

What persuades

On summary judgment in products/consumer cases he separates damages theories rather than ruling all-or-nothing: punitive damages can be knocked out as a matter of law while a Mass. c. 93A multiple-damages claim survives if there is a genuine dispute over whether the defendant acted willfully or knowingly. Keep the willfulness record alive to preserve the 93A multiplier.

“defendant's motion for summary judgment is GRANTED in part as to any claim for punitive damages arising out of tortious conduct and DENIED in part as to the claim for multiple damages under Mass. Gen. Laws ch. 93A.”

On fee awards he applies the First Circuit lodestar strictly: he limits recovery to work that is a 'predictable result' of the sanctioned conduct (denying Hamm-laptop motion-to-compel/forensics fees as outside the spoliation scope), cuts hours that the movant fails to segregate from ordinary litigation work (50% haircut), and trims hours he finds excessive for the size of the task (143.7 -> 80 hours for a ~25-page motion). Submit segregated, contemporaneous, right-sized time records.

“143.7 hours is an unreasonable expenditure of time for a relatively short, straightforward motion and argument. Eighty hours of attorney time is a more appropriate amount to spend on such a motion.”

In patent cases he is willing to invalidate method claims at summary judgment under 35 U.S.C. 101: he applies the Alice/Mayo two-step rigorously and finds an abstract idea with no inventive concept where the claimed steps amount to a conventional sequence (here, a calibration placement followed by a more accurate placement). A patentee defending eligibility should marshal a concrete, non-conventional inventive concept, not just point to the field of use.

“U.S. Patent No. 6,776,327 claims subject matter that is not patentable under 35 U.S.C. 101 and is therefore invalid.”

He reads pleadings by their facts, not their labels: a plaintiff may proceed on a legal theory (here, an FCA 'false-certification' theory) it never expressly named, so long as the complaint alleged the supporting facts -- 'it is factual allegations, not legal theories, that must be pleaded.' And he will equitably let a party adjust its strategy (file a successive summary-judgment motion, reopen limited discovery) when a mid-litigation change in controlling law shifts the legal ground. Plead the facts for every viable pathway even if you lead with one theory.

“The fact that 'false certification' was never explicitly stated as a theory of liability in the complaint is of no moment -- it is factual allegations, not legal theories, that must be pleaded in a complaint.”

Procedural preferences

He extends latitude to pro se litigants on procedural missteps: a Rule 12(b)(5) service failure is cured with a 30-day extension rather than dismissal where the defendant shows no prejudice -- but pro se status alone is 'not automatically enough to constitute good cause' under Rule 4(m).

“it is the practice of this Court to grant some latitude to pro se plaintiffs who make procedural missteps ... neither have defendants shown that they would suffer prejudice if the time for service was extended.”

Cautions

He treats FTCA administrative exhaustion as a non-waivable jurisdictional bar: a tort claim against the United States (or a federal officer in the FTCA's ambit) is dismissed under Rule 12(b)(1) if no administrative claim was filed with the agency first. File the SF-95/agency claim before suing.

“Failure of a claimant to exhaust her administrative remedies is a non-waivable, jurisdictional bar to bringing suit in federal court under the FTCA ... this court does not have subject-matter jurisdiction over this claim.”

He treats federal (impossibility) preemption as a fact-intensive affirmative defense the DEFENDANT must prove with 'clear evidence' (Wyeth v. Levine): a drug manufacturer cannot win summary judgment on preemption unless it shows, on undisputed facts, both that the FDA 'changes being effected' (CBE) process was unavailable to strengthen the warning and that there is clear evidence the FDA would have rejected the change. Failure-to-warn plaintiffs should develop a record that the manufacturer could have unilaterally strengthened the label via CBE.

“GSK has not proved, based on the undisputed facts, either (1) that the CBE process was unavailable to it to make more substantial warnings ... or (2) that there is 'clear evidence' that the FDA would not have approved a label including such warnings.”

Motion outcomes

Counted from classified signed orders only. Percentages are shown only where the sample is large enough to be meaningful; smaller samples are reported as raw counts.

Summary judgment
N = 9
Granted: 2Granted in part: 2Denied: 3Moot / procedural: 2 counts only
Motions to dismiss
N = 8
Granted: 4Granted in part: 1Denied: 1Moot / procedural: 2 counts only
Motion to exclude
N = 3
Granted in part: 1Denied: 2 counts only
Motion for claim construction
N = 1
Denied: 1 counts only
Motion for reconsideration
N = 1
Denied: 1 counts only
Motion for attorney fees
N = 1
Granted in part: 1 counts only
Motion for entry of judgment
N = 1
Granted: 1 counts only
Motion for leave
N = 1
Granted: 1 counts only

A "1 of 1" is one ruling, not a tendency. Treat small samples as illustrative, not predictive.

Signed rulings

A grounded sample of orders signed by this judge, with the verbatim dispositive language.

Griffin v. FBIRA Boston / Gagne
1:23-cv-11954 · 2024-05-22
Motions to dismiss (defendant) Granted

“defendants' motions to dismiss pursuant to Fed. R. Civ. P. 12(b)(1) for lack of jurisdiction and 12(b)(6) for failure to state a claim are GRANTED and the complaint is dismissed.”

Rivera v. Department of Children and Families
1:14-cv-10613 · 2014-07-21
Motions to dismiss (defendant) Granted

“Accordingly, the motion to dismiss is GRANTED, and the complaint is DISMISSED.”

Morales v. Spencer
1:13-cv-12423 · 2014-05-14
Motions to dismiss (defendant) Denied

“The motion to dismiss is DENIED without prejudice to its renewal.”

Nakanwagi v. Executive Office of the Trial Court
1:23-cv-10533 · 2025-06-06
Summary judgment (defendant) Granted

“For the foregoing reasons, defendant's motion for summary judgment is GRANTED.”

Elliston v. Wing Enterprises (Little Giant Ladder)
1:15-cv-11739 · 2016-12-02
Summary judgment (defendant) Granted in part

“defendant's motion for summary judgment is GRANTED in part as to any claim for punitive damages arising out of tortious conduct and DENIED in part as to the claim for multiple damages under Mass. Gen. Laws ch. 93A.”

Insulet Corporation v. EOFlow Co., Ltd.
1:23-cv-11780 · 2024-12-23
Motion for attorney fees (plaintiff) Granted in part

“plaintiff Insulet Corporation is awarded $10,677.98 in fees and expenses for the incremental discovery that it had to perform due to the spoliation and $81,288.90 for the fees and expenses incurred to bring the motion for an adverse-inference instruction. The total award of $91,966.88 is imposed against defendants Ian Welsford, Nephria Bio, Inc., EOFlow Co., Ltd., and EOFlow, Inc., jointly and severally.”

North America Photon Infotech, Ltd. v. Acquia, Inc.
1:22-cv-12052 · 2025-09-24
Motion for reconsideration (plaintiff) Denied

“For the foregoing reasons, plaintiff's motion for reconsideration is DENIED.”

Palomar Technologies, Inc. v. MRSI Systems, LLC
1:18-cv-10236 · 2020-05-28
Summary judgment (defendant) Granted

“The motion of defendant MRSI Systems, LLC for summary judgment on the issue of patentability under 35 U.S.C. 101 is GRANTED ... U.S. Patent No. 6,776,327 claims subject matter that is not patentable under 35 U.S.C. 101 and is therefore invalid.”

Summary judgment (plaintiff) Denied

“the motion of plaintiff Palomar Technologies, Inc., for summary judgment on the same issue is DENIED.”

Summary judgment (plaintiff) Moot / procedural

“The remaining motions of Palomar Technologies, Inc., for summary judgment are DENIED as moot.”

In re Zofran (Ondansetron) Products Liability Litigation
1:15-md-02657 · 2019-02-05
Summary judgment (defendant) Denied

“For the foregoing reasons, defendant's motion for summary judgment based on federal preemption is DENIED.”

United States v. Regeneron Pharmaceuticals, Inc.
1:20-cv-11217 · 2025-08-04
Motion for leave (plaintiff) Granted

“the motion of the United States for leave to file a second motion for partial summary judgment on the issues of falsity, materiality, and causation under a false-certification theory of FCA violation is GRANTED. The government's request for a limited reopening of discovery is also GRANTED.”

Massachusetts v. Wampanoag Tribe of Gay Head (Aquinnah)
1:13-cv-13286 · 2019-06-19
Motion for entry of judgment (plaintiff) Granted

“absent clear direction from the Court of Appeals, the Court will not reverse its judgment as to an issue that was never appealed. The Court will therefore enter a final judgment providing that any gaming facility ... is not subject to state and local laws and regulations concerning gaming ... [but] is otherwise subject to state and local regulation, including any applicable permitting requirements.”

Jiang v. Kobe Japanese Steakhouse, Inc.
1:22-cv-11867 · 2023-07-17
Motions to dismiss (defendant) Moot / procedural

“Defendants' original motion to dismiss (Docket No. 12) is DENIED without prejudice as moot.”

Motions to dismiss (defendant) Moot / procedural

“Defendants' second motion to dismiss (Docket No. 38) is DENIED without prejudice as moot.”

Caseload & timing

From public federal docket records for this judge.

Median case duration in the sampled dockets: 218 days (N = 6).

Median motion-to-ruling time: 116 days (N = 1).

Senior U.S. District Judge (former Chief 2020-2025), Boston. His docket includes nationally significant matters: Estados Unidos Mexicanos v. Smith & Wesson (Mexico's gun-industry suit, 1:21-cv-11269), Singular Computing v. Google (AI-chip patent, 1:21-cv-12110), Insulet v. EOFlow (trade secrets, $452M verdict, 1:23-cv-11780), the In re Zofran (ondansetron) products-liability MDL (1:15-md-02657), and U.S. v. Regeneron (FCA/AKS, 1:20-cv-11217). Sampled terminated dockets span products liability (Wood v. Philips, Shaffer v. Boston Scientific), ERISA (Groden v. Buck Point), employment (Lurie v. Securitas), and immigration (Luz v. USCIS). No quantitative nature-of-suit census computed this pass.